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hospitalar e custo do procedimento. Métodos: A partir do sistema de faturamento 
do HIAE foram selecionados 538 procedimentos de septoplastia com turbinecto-
mia e sinusectomia realizados no ano de 2011 que utilizaram as técnicas com-
paradas neste estudo. Foram incluídos na análise 517 pacientes, 56 procedimentos 
utilizando o microdebridador e 461 utilizando a técnica convencional. Em média, 
os pacientes que utilizaram o microdebridador possuíam uma faixa etária mais 
elevada e um percentual maior dos pacientes apresentaram diagnóstico de sinusite 
crônica. ResultAdos: Em relação à média de tempo de permanência hospitalar 
esta foi maior no grupo do microdebridador (28 horas versus 22 horas no grupo 
da técnica convencional, p= 0,002). A quantidade média de unidades de cola e de 
hemostático foi maior no grupo que utilizou o microdebridador. Não houve difer-
ença estatística entre os grupos nos desfechos de tempo de cirurgia e nas taxas de 
readmissão hospitalar. No desfecho de dor no pós operatório imediato a diferença 
entre os grupos foi estatisticamente significativa (p = 0,006), indicando um per-
centual maior de pacientes com escore de dor acima de 5 sendo tratados com o 
microdebridador, quando comparado com o grupo convencional. Considerando-se 
o custo do procedimento com a técnica convencional como referência, o uso do 
microdebridador resultou em um aumento médio de 17,4% em relação à técnica 
convencional. ConClusões: O uso do microdebridador não se mostrou favorável 
nos desfechos avaliados, tendo em vista um aumento do tempo de permanência do 
paciente, uso de colas e hemostáticos em maior quantidade que a técnica conven-
cional e o custo do procedimento foi significativamente mais alto.
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objeCtives: Economic burden in Chronic Obstructive Pulmonary Disease (COPD) 
patients with varying levels of dyspnoea is largely unknown. The objective of this 
retrospective analysis was to estimate the resource use and the associated costs 
incurred by COPD patients with increasing levels of dyspnoea with or without fre-
quent exacerbations. Methods: A retrospective cohort of prevalent COPD patients 
was identified in the Clinical Practice Research Datalink (CPRD). All patients who had 
at least 12 month pre- and post- cohort entry date (1st prevalent COPD diagnosis 
confirmed by spirometry ≥ April 1, 2009) recorded were included in the analysis. 
Patients were categorised as having none, 1 or 2+ exacerbations in the 12 months 
post cohort entry and further classified using Medical Research Council (MRC) dysp-
noea scale. Study outcomes included general practitioner (GP) visits, community 
treated exacerbations (medical dg for exacerbation or ATB+OCS Rx), hospital treated 
exacerbations and all-cause hospitalisations excluding COPD exacerbations. The 
costs associated with the estimated resource use were calculated using National 
Health Service (NHS) reference costs for 2010-11. Results: The cohort consisted 
of 51,641 COPD patients with 27,764 (53.8%), 12,585 (24.4%) and 11,292 (21.9%) hav-
ing experienced none, 1 and 2+ annual exacerbations post cohort entry. Among all 
patients, the estimated annual COPD management costs, excluding the costs of 
medications, were £1,597, £1,849, £2,298, £2,745 and £3,579 with increasing levels 
of dyspnoea (MRC grade 1-5). The equivalent cost ranges by exacerbation frequency 
were £1,267-£2,235, £2,021-£3,447 and £2,627-£4,709 for patients with none, 1 or 2+ 
annual exacerbations, respectively. ConClusions: Increase in COPD management 
costs with increase in level of dyspnoea occurred in all exacerbation frequency 
groups. Better symptom control and disease management strategies in primary 
care setting may help reduce COPD costs significantly.
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objeCtives: Smoking is the single most preventable cause of disease and death all 
around the world. Our objective was to quantify the disease burden associated with 
smoking in Argentina, Bolivia, Brazil, Chile, Colombia, Mexico and Peru. Methods: 
The project began with a survey to health Decision Makers (DM) to explore country-
specific information needs. The development stage involved the harmonization of 
a methodology to retrieve local relevant parameters and develop the model struc-
ture. A microsimulation HEM was built considering the availability and quality of 
epidemiological data and relevant outcomes were conceived to suit the identified 
information needs of DMs . It considers all tobacco-related diseases: heart, cerebro-
vascular and chronic obstructive pulmonary disease, pneumonia/influenza, lung 
cancer and nine other neoplasms. A systematic search on effectiveness, local epide-
miology and costs studies was undertaken to populate the model. Calibration and 
validation was performed for each country. Predicted event rates were compared 
to the published rates used as model inputs. External validation was undertaken 
against epidemiological studies not used to provide input data. Results: The cali-
brated model showed all simulated event rates falling within ±10% of the sources 
and a high correlation between published data and model results. In these seven LA 
countries, tobacco is responsible of 259,126 deaths each year. The diseases attrib-
utable to smoking cause a total of 1∙90 million years of life lost due to premature 
death, 0∙64 million years of life lost due to disability and at least 27 billion dollars 
(USD dollars 2013) in direct medical costs each year. ConClusions: Tobacco use is 
real world treatment patterns in Insomnia patients and majority of these stud-
ies focused on benzodiazepine users. The rate of medication use in Insomnia 
patients is fairly low and rates were ranging from 17% to 75%. There were a total 
of 11 trials published testing Eszopiclone use, 10 trials each on Ramelteon and 
Zolpidem, 4 trials on Indiplon, 3 trials on Gaboxadol, 3 trials on Doxepin use in 
patients diagnosed with Insomnia. Several patient reported outcomes measures 
were used in the assessment of various clinical trials. ConClusions: There 
were a variety of agents being used to treat insomnia; while benzodiazepines 
and non-benzodiazepines were largely popular. Products in development need to 
be studied further to determine whether their new mechanisms of action were 
truly beneficial for treatment.
RESPiRatoRy-RELatEd diSoRdERS – Clinical outcomes Studies
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objeCtives: To investigate the patient’s acute asthma characteristics, and iden-
tify predictors of asthma control in a population of asthma patients from five 
Latin American countries. Methods: Adults and parents of adolescents (12-17 
years) with a physician diagnosed asthma and asthma medication use or asthma 
attacks in the past year were surveyed as part of the 2011 Latin America Asthma 
Insights and Management (AIM) survey. Using Global Initiative for Asthma (GINA) 
guidelines as a reference, respondents were categorized into three levels of asthma 
control: well-controlled, partly- controlled, and uncontrolled. Chi-square tests 
and adjusted logistic regression were used to determine odds ratios (ORs) to 
assess the relation of degree of asthma control with frequency of sudden asthma 
episodes, frequency of asthma symptoms, duration of episodes, day-and night 
time symptoms, utilization of rescue medications, and asthma episodes season-
ality. Results: Data from 2168 adults and parents from asthma patients ≥ 12 
years survey was analyzed. Seven percent (7%) of the patients are controlled, 57% 
partially controlled, and 36% uncontrolled. Adjusted logistic regression models 
showed that patients whose asthma was uncontrolled were significantly more 
likely to have acute sudden asthma episodes compared to patients whose asthma 
was controlled either partially or fully. Similarly, patients with uncontrolled 
asthma were significantly more likely to have higher frequency of asthma episodes 
in most days of the week, increased day and night symptoms than those asthmat-
ics who were controlled ConClusions: Patients who did not have well-controlled 
asthma had more acute episodes as compared to patients whose asthma was 
well-controlled. Our results strongly suggest that the acute asthma requires a 
significant effort to decrease its severity.
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objeCtives: Graphic health warnings (GHWs) on cigarette packages have been 
found to be significantly associated with increased awareness of smoking-related 
health hazards as well as behavior change. Legislations on GHWs have recently 
been endorsed and GHWs have now been introduced in Qatar. This study aims to 
evaluate the general public’s awareness, beliefs and perceptions on anti-tobacco 
GHW labels on cigarette packs prior to the introduction of the new law. Methods: 
A cross-sectional survey using a pretested 23-item questionnaire was conducted 
among randomly approached adults in Qatar. Data were analyzed using the IBM 
SPSS® version 19. Responses were analyzed by smoking status (ever-smokers 
vs. never-smokers) to ascertain how these two distinct groups differed in their 
awareness and perceptions related to health warning messages. The demographic 
characteristics and other outcomes of interest were compared using χ 2 or Fishers 
Exact tests. Results: A total of 500 participants (59% male) responded to the sur-
vey. Most notably, ever-smokers did not significantly differ from never-smokers 
on awareness of GHW. About one-third of the respondents had no idea about any 
specific text warning messages on tobacco products sold and nearly 45% of them 
did not know what a GHW was. Furthermore, a substantial proportion (more than 
20%) of the respondents in both groups did not believe that introducing GHWs 
will enhance smoking behavior change. Non-smokers generally tended to have 
more positive attitudes than smokers toward the perceived impact of GHWs (p < 
0.05). ConClusions: A substantial proportion of the general public in Qatar had 
poor awareness about GHWs. This study has important implications on the needs 
to increase awareness about the value of GHWs as well as calls for further research 
to determine the effectiveness of GHW labels on cigarette packages in Qatar and 
the greater Middle Eastern region, where legislations on GHWs are still at infancy.
RESPiRatoRy-RELatEd diSoRdERS – Cost Studies
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objetivos: O objetivo deste estudo foi comparar as técnicas cirúrgicas com uso 
do microdebridador em relação à técnica convencional nos procedimentos de sep-
toplastia com turbinectomia e sinusectomia, quanto ao tempo de cirurgia, tempo 
de hospitalização, uso de colas e hemostáticos, escore de dor, taxa de readmissão 
